Ark Therapeutics Group plc (AKT: LSE) ("Ark" or "the Company"), announces that it has filed documentation with the European Medicines Agency ("EMA") in relation to its request for re-examination of the marketing approval application ("MAA") for Cerepro®, Ark's novel gene based therapy for the...